NVAX Novavax Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVAX

Price (delayed)

$3.97

Market cap

$555.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.41

Enterprise value

$205.77M

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights
Novavax's EPS has increased by 36% YoY and by 14% QoQ
NVAX's gross margin is up by 19% year-on-year
Novavax's debt has shrunk by 58% YoY but it has increased by 3.1% QoQ
The revenue has plunged by 50% YoY and by 6% from the previous quarter
NVAX's gross profit is down by 41% YoY and by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novavax.com/
Peers: AGEN SRPT BCRX EBS

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
139.95M
Market cap
$555.61M
Enterprise value
$205.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
Earnings
Revenue
$983.71M
EBIT
-$528.62M
EBITDA
-$487.39M
Free cash flow
-$772.77M
Per share
EPS
-$5.41
Free cash flow per share
-$7.67
Book value per share
-$6.04
Revenue per share
$9.76
TBVPS
$16.57
Balance sheet
Total assets
$1.8B
Total liabilities
$2.51B
Debt
$229.08M
Equity
-$716.93M
Working capital
-$491.25M
Liquidity
Debt to equity
-0.32
Current ratio
0.7
Quick ratio
0.54
Net debt/EBITDA
0.72
Margins
EBITDA margin
-49.5%
Gross margin
65.1%
Net margin
-55.4%
Operating margin
-57.6%
Efficiency
Return on assets
-32.6%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-325.6%
Return on sales
-53.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
2.06%
1 week
-7.24%
1 month
-19.64%
1 year
-55.69%
YTD
-17.29%
QTD
-16.95%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$983.71M
Gross profit
$639.94M
Operating income
-$566.51M
Net income
-$545.06M
Gross margin
65.1%
Net margin
-55.4%
The operating margin has dropped by 77% year-on-year but it has increased by 3.5% since the previous quarter
Novavax's net margin has shrunk by 67% YoY and by 6% QoQ
The revenue has plunged by 50% YoY and by 6% from the previous quarter
NVAX's gross profit is down by 41% YoY and by 6% QoQ

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
0.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
Novavax's EPS has increased by 36% YoY and by 14% QoQ
Novavax's equity has decreased by 13% YoY and by 6% QoQ
NVAX's P/S is 97% below its 5-year quarterly average of 13.5 and 18% below its last 4 quarters average of 0.5
The revenue has plunged by 50% YoY and by 6% from the previous quarter

Efficiency

How efficient is Novavax business performance
Novavax's return on sales has shrunk by 68% YoY and by 5% QoQ
NVAX's return on assets is down by 23% year-on-year and by 6% since the previous quarter

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 29% lower than its total liabilities
Novavax's total assets has decreased by 20% YoY but it has increased by 8% QoQ
The total liabilities has declined by 13% year-on-year but it has increased by 8% since the previous quarter
Novavax's debt is 132% higher than its equity
NVAX's debt to equity has surged by 63% year-on-year and by 3% since the previous quarter
Novavax's debt has shrunk by 58% YoY but it has increased by 3.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.